Presenting Companies
AccuLine is developing CORA, a system to help primary care physicians detect coronary artery disease through a rapid, non-invasive test. CORA integrates sensor hardware with ML-based models to provide objective, accurate assessments at the point of care. Unlike traditional cardiac diagnostics that require referrals, imaging, or stress-based evaluations, CORA is designed to be accessible, easy to use, and clinically validated for primary care settings. By enabling earlier detection and reducing unnecessary downstream testing, CORA supports timely intervention, improves clinical decision-making, and reduces overall healthcare costs. AccuLine is backed by strong investors such as eHealthventures, Macabbi Healthcare Services and Mayo Clinic.
Akridata delivers next-generation AI solutions for visual inspection in manufacturing. Our platform empowers data science and quality teams to curate and manage large datasets, build state-of-the-art AI models, and deploy AI-assisted human inspection systems that enhance accuracy and throughput. Trusted by leading manufacturers in automotive, medical devices, and industrial sectors, Akridata helps streamline quality control with precision, speed, and scale.
Amplifi Vascular is a medical device company focused on improving hemodialysis access by enabling reliable, early maturing forearm AVFs. The Amplifi Vein Dilation System delivers a controlled, temporary therapy to enlarge target veins prior to surgical fistula creation, aiming to increase success rates, reduce catheter days and re-interventions, and lower overall costs of care.
Founded by seasoned medtech executives and venture-backed since 2020, Arga Medtech is transforming cardiac electrophysiology with its groundbreaking Coherent Sine-Burst Electroporation (CSE) technology. The company’s unique all-in-one catheter system streamlines complex ablation procedures for atrial fibrillation (AF) and other arrhythmias, delivering efficient, precise, and tissue-specific ablation with exceptional safety. Optimized for persistent AF and cases requiring ablation beyond pulmonary vein isolation, Arga’s platform enables electrophysiologists to perform advanced lesion sets and tailored strategies in a single procedure. Early clinical data on the treatment of atrial fibrillation show outstanding efficacy and zero major complications, positioning Arga’s CSE system to set a new standard in electrophysiology. With strong funding and leadership, Arga is advancing pivotal IDE trials and scaling towards commercialization.
AseptiScope, Inc. is a privately funded, San Diego-based clinical innovation company in early commercial phase. Led by a team of clinical experts, medical researchers, and practicing physicians, the company's mission is to design, develop, manufacture, and commercialize novel solutions that provide "Infection Protection for Clinician & Patient." Its flagship product, The DiskCover System, is the first and only technology to provide an evidence-based, touch-free solution to stethoscope contamination, a vector that touches US patients 5 billion times every year.
Assistive Technology Development (ATDev) creates robotic and telehealth-enabled devices that empower people to live more independently. Our flagship product, Reflex, is a lightweight knee rehabilitation system that provides both passive and active therapy at home while keeping patients and clinicians connected through real-time data. Founded by engineers, clinicians, and wheelchair users, ATDev’s mission is simple: mobility for all. We are redefining recovery through accessible, high-quality technology that restores freedom and dignity to millions.
Azalea Vision is a health-tech company pioneering the first intelligent, lens-embedded system designed to sense, adapt, and connect in real time. The first application is focusing on health monitoring through the tear fluid. Our technology integrates adaptive optics, custom microelectronics, and liquid-crystal systems within a contact lens—creating a scalable platform for both real-time biosensing health monitoring and vision correction.
BOYDSense is a pioneering healthtech company revolutionizing metabolic health monitoring by using non-invasive breath analysis instead of needles to track glucose and metabolic states. This breakthrough offers over 1 billion underserved individuals with pre-diabetes, early-stage Type 2 diabetes, obesity, a simple, engaging, and actionable way to manage their health. The company’s clear two-device rollout plan includes a consumer launch end 2026 followed by a medical launch in 2028, backed by proven science from 4 clinical trials, extensive intellectual property, and a highly experienced team with multiple successful exits.
BrainScope is a leading neurotechnology company advancing brain health through objective, AI-powered insights derived from brain electrical activity (EEG). Its proprietary platform analyzes EEG data from any source using advanced machine and deep learning to deliver rapid, radiation-free, accessible and cost-effective biomarkers - greatly expanding the clinical utility of traditional EEG. BrainScope's device for head injury assessment was the first device in neurology cleared by the FDA under the AI/Machine Learning-Enabled Medical Device category. BrainScope has commercialized its first set of FDA-cleared biomarkers for mild brain injury assessment (both brain bleeds and concussions) with remarkable outcomes in major U.S. health systems, which include ~50% reduction in unnecessary head CTs, substantial reductions in patient length of stay in emergency departments, and high utility for concussion clinics, personal injury cases and sports. The company is now advancing novel biomarkers for early Alzheimer’s detection, ARIA assessment, rapid stroke evaluation, concussion subtyping, military blast exposure, and others.
At Dasion we are utilizing novel Geometric Unified Learning (GUL) to bring fast, interpretable decision making tools to healthcare practitioners, reinventing the relationship between AI and medicine. We build systems that expedite health data interpretation and diagnosis, allowing healthcare professionals to spend more time doing what they do best, caring for their patients.
FreMon Scientific specializes in next generation medical devices that ensure precise thawing of life saving therapies. ZipThaw is an FDA-approved Class II medical device, made in the USA, for the warming and thawing of plasma and red blood cells in hospitals and blood banks. Data also demonstrate ZipThaw's superior recovery and viability of raw material and engineered cells for cell therapies. With a recurring revenue model, more than 200 devices have been installed in the market, from the US military to the nation’s top hospitals and academic research labs. FreMon Scientific (San Diego, CA) is raising capital to launch the Gen II ZipThaw, build out commercial capabilities, and scale the company.
GenBio AI operates at the intersection of artificial intelligence and biology, developing multiscale foundation models to understand and predict biological processes across all scales of life. Through its AI-driven Digital Organism (AIDO), the company enables predictive disease modeling, drug discovery acceleration, and bioengineering innovation. Founded by leading AI and computational biology experts from top global institutions, GenBio AI integrates pan-modal biological data to drive real-world biomedical impact. With hubs in Palo Alto, Paris, and Abu Dhabi, the company fosters international collaboration to advance AI-driven biology.
Heteron Biotechnologies develops hand-held breath diagnostic devices that achieve laboratory-level accuracy at a fraction of traditional testing cost. The company’s flagship H. pylori device has demonstrated 100% concordance with gold-standard 13C-UBT technology and is engineered for large-scale population screening to prevent gastric cancer. With a low-cost design, AI-assisted signal processing, and sterile disposable mouthpieces, the platform enables rapid deployment across primary care, pharmacy networks, and global health programs. Heteron is currently raising $2M to complete FDA clearance for the H. pylori testing device in the United States.
Based in Providence, Rhode Island, Lenoss Medical is a medical device company dedicated to the design, development and commercialization of a novel biological implant and associated delivery instrumentation for the treatment of painful vertebral compression fractures. Lenoss Medical developed the only fully biological solution for treating VCFs. The OsteoPearl Biological Augmentation is a minimally invasive spinal implant designed to stabilize the spinal fracture and create an environment for restoration and healing. Immediate stability is created by the structural matrix, introducing both osteoinductive and osteoconductive properties.
Magellan Biomedical provides solutions for the diagnosis of cardiovascular disease. The product provided is a cath-pilot that allows the control & navigation of any off-the-shelf guidewire to facilitate the crossing of arterial occlusions during peripheral revascularization procedures. The Cath-Pilot helps in reducing failure rates, procedure times, and overall cost of peripheral revascularization procedures. It also provides tracking of the guidewire tip.
MAUI Imaging has developed a unique hardware/software solution, protected by over 100 patents, that uses ultrasound to image multiple different types of tissue simultaneously. This unique ability to image simplifies the capture methodology. The ability to capture volumetric data sets immediately, opens up markets previously unavailable to ultrasound.
Medical 21 is reshaping the future of cardiac bypass surgery by developing an artificial artery that will eliminate the need for blood vessel harvesting. This significant advancement can help reduce the systemic and painful challenges
that traditional Coronary Artery Bypass Graft surgery present.
Merge offers a collaborative platform that benefits all stakeholders; Decreasing traffic and door swings in the operating room, while maintaining the device rep’s ability to provide expert support on their products, all from a remote location.
Morphic Medical (formerly GI Dynamics Inc.) is the developer of RESET® (EndoBarrier), an endoscopically delivered device therapy that offers a non-surgical, alternative treatment for the treatment of type 2 diabetes and obesity. RESET is not approved for sale in the United States and is limited by federal law to investigational use only.
Nitinotes developed EndoZip™, the first approved automated ESG suturing platform for the treatment of obesity. EndoZip™ recently received CE Mark treatment the of obesity, making procedures simpler, faster, and more consistent, transforming the way obesity is managed endoscopically. EndoZip™ will expand access to patients through more gastroenterologists and surgeons as a result of the easier learning curve. Earlier this year the FDA approved our IDE trial. We are currently raising expansion capital in a Series C to support our commercial and US regulatory activities.
Noor Sciences has developed a validated AI-powered, non-invasive fertility diagnostic platform to revolutionize IVF outcomes. Our Em-Lux™ system uses proprietary multi-modal imaging and trade-secret biomarkers to assess embryo and egg viability to increase IVF success rates, addressing the $48B global fertility market.
Opening Eyes Beautifully!! Osheru is dedicated to leading minimally invasive technology for excess skin removal. Ziplyft, our innovative device, streamlines eyelid surgery for patients and surgeons, while expanding the market for this procedure.
Peerbridge Health is transforming cardiac diagnostics with a hospital-grade wearable ECG platform that brings high-fidelity cardiac data to any care setting. Our technology integrates advanced signal processing, AI-driven analytics, and a highly scalable workflow to accelerate diagnosis while improving patient experience. By operating at ultra-low cost and leveraging existing reimbursement codes, Peerbridge enables practices to expand diagnostic capacity and generate immediate economic value without disrupting established workflows. The platform is scaling across cardiology, primary care, and remote monitoring markets as providers seek solutions that are both clinically superior and financially beneficial. With strong differentiation and a robust product roadmap, Peerbridge is positioned to become a leader in next-generation cardiac care.
PredxBio is a spatial insights company powering next-generation cancer therapeutics with its AI-driven spatial biomarkers. Through its proprietary SpaceIQ™ platform, PredxBio uncovers mechanisms of action and predicts patient outcomes with over 90% accuracy—validated across multiple pharma collaborations, cancer indications, and multi-omic datasets. By transforming multiplexed biopsy images and spatial transcriptomic/proteomic data into actionable insights—and revealing the hidden network biology of cancer—PredxBio is setting new standards for biomarker discovery and clinical research. The company’s technology is actively deployed in paid engagements with leading pharmaceutical companies and research institutions, accelerating drug discovery and advancing personalized medicine for cancer patients globally. For more information, visit www.predxbio.com
Rejuvenan Global Health has created a truly unique, digital personal health platform for corporate wellness and health. Our core mission is to utilize these digital interventions to deliver clinically proven behavioral modifications to prevent, treat and reverse lifestyle-induced chronic diseases. We have developed two proprietary sets of algorithms that incorporate the 2009 Nobel Prize-winning science of telomere biology: a Risk Detection Engine and a Treatment Recommendation Engine. These algorithms provide curated, personalized coaching and other interactive tools to drive behavioral change through the adoption of healthy lifestyle shown to reduce or reverse future disease risk and alter gene expression patterns for the better. Rejuvenan’s health platform collects data from users’ smart devices, blood tests, and direct input. Our platform then utilizes a 10-biomarker health assessment to deliver personalized coaching to improve each user’s nutrition, exercise, stress management and social support behaviors that are proven to lengthen telomeres—the ultimate measure of health. We have created an individualized roadmap to optimal health.
Retia Medical is transforming the management of at-risk patients through AI-powered cardiovascular monitoring that enables improved outcomes at lower costs. Retia serves a global opportunity of $8 Billion spanning in-hospital monitoring, predictive algorithms, and remote patient monitoring (RPM). The Company an installed base of 75 hospitals, including 500 beds at Cleveland Clinic. Retia is raising $5-8 million to launch its new clinical intelligence platform, Argos Infinity, accelerate global expansion, and pursue regulatory clearance of its new non-invasive AI algorithms.
Rheoxtech is a medical device company that has developed the RheOx™ Reperfusion System, a first-in-class patented technology designed to reduce ischemia–reperfusion injury during acute myocardial infarction (AMI). In the U.S., there are over 805,000 acute heart attacks each year, and an estimated ~40% of these patients are vulnerable to serious reperfusion injury—damage that occurs when oxygenated blood flow is restored too quickly after a blocked coronary artery is opened. RheOx enables controlled, gradual reoxygenation the heart through the culprit coronary artery at the moment of reperfusion, protecting the myocardium and preserving the hearts in AMI patients, including those with cardiogenic shock. The system is designed to integrate seamlessly into existing cath lab workflows and is used alongside current PCI tools. In initial retrospective data, RheOx was associated with an ~80% reduction in mortality and a ~70% reduction in readmission/heart failure.
Transformative Biotech is advancing patented direct-to-PCR technologies that eliminate the complex extraction step, making gold-standard molecular testing accessible anywhere. Forged during the pandemic, our platform was validated on more than 590,000 clinical samples at Summit Biolabs, a former CLIA-certified laboratory in Colorado, and is protected by U.S. Patent #12,344,889, with five additional patents pending. Our impact: enabling PCR testing for infectious diseases @ANYWARE™, improving diagnosis and treatment to help save millions of lives each year.
TEECAD is quickly becoming a clinically inevitable part of the future of TEE procedures. As the world's first, FDA-cleared disposable camera that seamlessly connects to a transesophageal echocardiogram (TEE) probe, TEECAD provides physicians with real-time visualization during intubation and promotes more efficient and effective probe placement.
A platform that enables clinicians and nurses to continuously and remotely monitor a patient’s vital signs, reliably and undisturbed. Real-time, continuous monitoring enables, amongst other things, early detection of patient deterioration which leads to reductions in length of stay and treatment costs. Our wearables are small, flexible, waterproof, discreet and noninvasive. Data collected can be sent to medical record systems, 3rd party systems and connected devices.
X Nerve is a developer of an implantable device intended to treat obstructive sleep apnea. The company's device stimulates the vagus nerve that controls unconscious actions and can rapidly rewire brain functions, enabling clinicians to treat sleep disorders.